云南白药(000538) - 2014 Q4 - 年度业绩

Financial Performance - Total revenue for 2014 reached CNY 1,881,436.64 million, an increase of 18.97% compared to the previous year[3] - Net profit attributable to shareholders was CNY 250,607.65 million, reflecting a year-on-year growth of 7.95%[3] - Net profit excluding non-recurring gains and losses increased by 21.50% to CNY 226,673.13 million[3] - Basic earnings per share rose to CNY 2.41, up from CNY 2.23, marking a 7.95% increase[4] - Total assets at the end of the reporting period amounted to CNY 1,634,134.02 million, a 26.86% increase from the beginning of the year[3] - Total equity attributable to shareholders increased by 23.88% to CNY 1,118,506.57 million[4] - The weighted average return on equity decreased to 24.86%, down from 28.94%[3] Strategic Initiatives - The company implemented a "New Baidu, Big Health" strategy, focusing on refined management and marketing reforms[5] - Despite a sluggish market environment, the company maintained stable growth in key operational indicators[6] - The company did not issue any earnings forecasts or revisions for the reporting period[7]